This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Bipolar Disorder  • Psychopharmacology  • Drug Therapy  • Alert me on articles by topic

A Double-blind, Placebo-Controlled Trial of Tamoxifen

Ayegül Yildiz, MD; Sebnem Guleryuz, MD; Donna Pauler Ankerst, PhD; Dost Öngür, MD, PhD; Perry F. Renshaw, MD, PhD

Arch Gen Psychiatry. 2008;65(3):255-263.

Context  Findings that protein kinase C (PKC) activity may be altered in mania, and that both lithium carbonate and valproate sodium inhibit PKC-associated signaling in brain tissue, encourage development of PKC inhibitors as candidate antimanic agents.

Objective  To perform a controlled test of antimanic efficacy of the centrally active PKC inhibitor tamoxifen citrate.

Design  Three-week, randomized, double-blind, placebo-controlled, parallel-arms trial.

Setting  A university medical center inpatient psychiatric unit in Izmir, Turkey.

Patients  Sixty-six patients aged 18 to 60 years, diagnosed as having DSM-IV bipolar I disorder on the basis of the Structured Clinical Interview for DSM-IV, currently in a manic or mixed state, with or without psychotic features, with initial scores on the Young Mania Rating Scale (YMRS) greater than 20.

Intervention  Treatment with tamoxifen or identical placebo tablets for up to 3 weeks. Adjunctive lorazepam was allowed up to 5 mg/d.

Main Outcome Measures  Primary: change in YMRS scores; secondary: change in Clinical Global Impressions–Mania scores, weekly ratings of depression and psychosis, and adjunctive use of lorazepam.

Results  The 21-day trial was completed by 29 of 35 subjects randomized to receive tamoxifen (83%) and 21 of 31 given placebo (68%) (P = .25). Intent-to-treat analysis of available measures on all 66 subjects indicated that tamoxifen treatment yielded mean decreases in scores on the YMRS and Clinical Global Impressions–Mania of 5.84 and 0.73 point per week, respectively, compared with mean increases of 1.50 and 0.10 point per week, respectively, with placebo; both drug-placebo contrasts differed significantly (P < .001).

Conclusions  Tamoxifen demonstrated antimanic properties and was remarkably well tolerated. The findings encourage further clarification of the role of PKC in the pathophysiologic mechanism of bipolar I disorder and development of novel anti-PKC agents as potential antimanic or mood-stabilizing agents.

Trial Registration  clinicaltrials.gov Identifier: NCT00411203 and isrctn.org Identifier: ISRCTN97160532

Author Affiliations: Department of Psychiatry, Dokuz Eylül University Medical School, Izmir, Turkey (Dr Yildiz); Department of Psychiatry, Harvard Medical School, and McLean Hospital, Boston, Massachusetts (Drs Yildiz, Öngür, and Renshaw); Emergency Department, Altin Ordu Hospital, Izmir (Dr Guleryuz); and Institute for Medical Informatics, Biometry, and Epidemiology, Munich, Germany (Dr Ankerst).

RELATED ARTICLE

Clinical Trials in Bipolar Mania: Implications in Study Design and Drug Development
Mauricio Tohen
Arch Gen Psychiatry. 2008;65(3):252-253.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Atypical antipsychotics in bipolar disorder: the treatment of mania
Cookson
Adv. Psychiatr. Treat. 2008;14:330-338.
ABSTRACT | FULL TEXT  

Tamoxifen: An Intracellular Target for Treatment of Mania
JWatch Psychiatry 2008;2008:1-1.
FULL TEXT  

Clinical Trials in Bipolar Mania: Implications in Study Design and Drug Development
Tohen
Arch Gen Psychiatry 2008;65:252-253.
FULL TEXT